TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen and Outcome After Below Knee Amputations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to consent~* Non-traumatic indication for lower limb amputation~* Able to receive hyperbaric oxygen therapy~Exclusion Criteria:~* Unable to consent~* Contraindication to hyperbaric oxygen~* End stage renal disease on dialysis~* Current renal failure as measured by creatinine levels vs baseline change of more than 1 mg/dL and for whom dialysis is expected to be required with the next month~* Calciphylaxis~* Traumatic injuries that are the cause of the amputation~* Cancer being treated by chemotherapy, scheduled to be treated, or being treated or scheduled to be treated by radiation.~* Limb amputation secondary to ischemic complications from other operations~* Second amputation or reoperation on prior amputation~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperbaric Oxygen Plus Regular Care (Type: EXPERIMENTAL): Hyperbaric oxygen (2 hours at 2 atmospheres absolute) to be administered 1-2 times daily for up to 10 treatments after amputation. Usual care for patients with amputation will be administered in parallel.
- Regular Care (Type: NO_INTERVENTION): Usual care for patients with amputation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Diabetes and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women of any racial background~* Age \>= 40 years and \<= 75 years~* SBP\>= 130 mmHg and \< 140 mmHg or DBP \>= 85 mmHg and \< 90 mmHg, average of screening and randomisation visits (in absence of any antihypertensive medication)~* FG \>=100 mg/dl (5.6 mmol/l) and \< 126 mg/dl (7.0 mmol/l) between screening and randomisation (in absence of any antidiabetic medication)~* Waist circumference \>= 102 cm in men and \>= 88 cm in women.~Exclusion Criteria:~* SBP \>= 140 mmHg or DBP \>= 90 mmHg~* Any antihypertensive, antidiabetic or antiobesity medication at the time of or during the 6 months previous to randomisation~* Any current or previous cardiovascular or renal disease requiring continuous administration of Ds, ßBs, ACEIs, ARBs, CAs, and any other antihypertensive medication~* Any medical condition preventing adherence to lifestyle measures included in the protocol~* Hepatic disease as AST (SGOT) or ALT (SGPT) values equal or greater than two times the upper limit of normal~* Chronic renal dysfunction as serum creatinine \> 2.0 mg/dl~* Any gastrointestinal disorder interfering with drug absorption~* Known allergy or contraindications to ACEIs or ARBs~* Pregnant or lactating women; women in reproductive age not using recognized contraceptive methods~* Malignancy within the last 5 years~* Clinically significant autoimmune disorders~* Drug abuse or alcohol abuse within the last 5 years~* History of noncompliance to medical regimens~* Incapacity or unwillingness to sign the informed consent~* Participation in any investigational clinical trial within the last 3 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Diet, exercise and Enalapril (Type: EXPERIMENTAL): one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
- Diet, Exercise and Losartan (Type: ACTIVE_COMPARATOR): one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
- Diet, exercise and Placebo (Type: PLACEBO_COMPARATOR): one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Additional Insulin for Fat and Protein in Children With Diabetes Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 diabetes (for at least a year)~* On multiple daily insulin injections, including basal long-acting insulin and rapid-acting insulin before each meal.~* HbA1c \< 75 mmol/mol (9.0%)~* Participant and/or parent/legal guardian willing and able to give informed consent for participation in the study.~* Family have a freezer in which to safely store the test meals.~* In the Investigator's opinion, is able and willing to comply with all trial requirements.~Exclusion Criteria:~* HbA1c greater than 75 mmol/mol (9.0%)~* Child unwilling to agree to second insulin injection at a meal-time~* Untreated coeliac disease or other concomitant condition likely to affect BG control~* Food allergies (other than controlled Coeliac Disease)~* Vegetarians, vegans or patients with religious dietary restrictions (as the standard meal contains meat)~* Participant taking any glucose-containing medication concurrently

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (usual treatment) (Type: ACTIVE_COMPARATOR): Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
- Arm 2 (Type: ACTIVE_COMPARATOR): Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
- Arm 3 (Type: ACTIVE_COMPARATOR): Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HbA1C of 5.7% to 9.0% or a fasting blood glucose of greater than or equal to 100~* Participants that are diabetic should be stable on medications for at least 3 months prior to entering the study~* Neuropathy is most likely caused by impaired glucose regulation determined by medical or family history~* Autonomic neuropathy as defined by Toronto Neuropathy Expert Group 2010/2011 consensus criteria~* Medically stable at time of enrollment as determined by screening process~Exclusion Criteria:~* Neuropathy due to factors other than impaired glucose regulation determined by screening process~* Other severe medical illness or condition that would preclude safe participation in the study as determined by the study team~* Severe Autonomic Neuropathy that would limit study participation~* Musculoskeletal limitations that would preclude participation in balance assessment of protective stepping

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Muscle, Balance, and aerobic exercise (Type: EXPERIMENTAL): This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of IPF and NSIP, based on the American Thoracic Society/European Respiratory Society Consensus Conference~* age ≥ 18 years~* males/females~* signed informed consent~Exclusion Criteria:~* pregnancy~* breast feeding~* healthy volunteers~* paediatric cases~* patients in emergency situations~* patients legally incompetent~* patients who refuse to sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 68Ga-DOTANOC PET/CT in patients with IPF and NSIP (Type: OTHER): one arm study: all patients were studied by 68Ga-DOTANOC PET/CT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of the Pharmacist and Pharmacogenomics in the Care of Seriously Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* Age 18 years and older~* Palliative Medicine is consulted for the first time in either the outpatient setting for symptom management and plan to continue to follow up with the Palliative Medicine team in the outpatient setting for the foreseeable future.~* Insurance accepted at Mayo Clinic Arizona.~* Live within metro Phoenix area.~Exclusion Criteria:~* Vulnerable adults~* Under 18 years of age~* Pregnant Patients~* Subjects whose medical insurance requires use of specific pharmacies~* Non English Speaking Patients~* Patients that lack capacity for medical decision making~* Patients who live outside the metro Phoenix area~* Patients who are lost to follow up secondary to enrolling in hospice, die or failure to show or answer surveys within 2 months of enrollment.~* Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.~* Patient's previously established within the Palliative Medicine Clinic who receive ongoing Palliative Medicine services.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: NO_INTERVENTION): Standard care by Palliative Medicine physician
- Intervention Group A (Type: EXPERIMENTAL): Standard care by Palliative medicine physician plus pharmacist review of medications
- Intervention Group B (Type: EXPERIMENTAL): Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with cervical cancer, at any stage, before any anti-tumoral treatment.~2. Age ≥ 18 years.~3. Patient information and signature of the informed consent or her/his legal representative.~4. Patient having given her/his agreement for a second biopsy at diagnosis if the first one was performed outside of the center and was not cryopreserved.~Exclusion Criteria:~1. Person deprived of liberty or under supervision.~2. Inability to attend scheduled follow-up visits for any psychological, sociological or geographical reasons.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tumor biopsies and blood sampling (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: WHODAS-II for Patients With Nonspecific Low Back Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients seen for nonspecific low back pain, with or without referred pain~* Able to read and write~* Have signed the informed consent form~Exclusion Criteria:~* Central nervous system pathology (with or without treatment)~* Diagnosis of rheumatic inflammatory disease or fibromyalgia~* Red flags for underlying systemic disease~* Criteria for diagnosis of symptomatic herniated disc or symptomatic spinal stenosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the Combined WLI and Hyperthermia for GI Cancer Liver Metastasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1 Patients must have a diagnosis of pathologic proven gastrointestinal tract cancer~* 2 Unresectable and unsuitable to other local modalities~* 3 Not responded and/or unsuitable to chemotherapy~* 4 Eastern Cooperative Oncology Group ECOG) performance status 0 to 3~* 5 Assessment by colorectal tumor board (surgeon, radiation oncologist and medical oncologist participated)~* 6 Age ≥ 20~* 7 Agreement of study-specific informed consent~* 8 Blood work requirements~  * Absolute neutrophil count (ANC) ≥ 1,500 /mm3, Platelet ≥ 50,000/mm3, Hgb ≥ 8 g/dl~ * Liver function test(LFT): Total bilirubin\<3.0 mg/dL, International normalized ratio(INR) \< 1.7, Albumin ≥ 2.8g/dL, Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT)\< 6 X normal~ * Serum creatinine \< 1.5 X normal, or Creatinine clearance rate (CCr) ≥ 60 mL/min~* 9 Child-Pugh score 10 or less within 1 week before WLI~* 10 Childbearing potential woman, consent contraception at least 6 months~* 11 Stable breathing more than 5 minutes~Exclusion Criteria:~* 1 Life expectancy less than 8 weeks~* 2 Pregnant and/or breastfeeding woman~* 3 Previous upper abdominal RT history~* 4 Uncontrolled ascites or hepatic encephalopathy~* 5 Unstable respiration due to pleural effusion, chronic obstructive pulmonary disease COPD) etc

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined hypertermia and RT (Type: EXPERIMENTAL): Combined hypertermia and radiothearpy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have received cyclosporine-based immunosuppressive therapy for more than 6 months， and have maintained a stable regimen for at least 8 weeks before enrollment~* The trough blood level of cyclosporine maintained at 50-200ng/ml at least 4 weeks before enrollment~* SCr\< 200 μmol/l ( 2.3 mg/dl)~* Females of childbearing potential must have a negative pregnancy test within 48 hrs prior to randomization and reliable methods of contraception should be started 4 weeks prior to and during the whole study~* Understand and sign the approved informed consent form~Exclusion Criteria:~* Patients who have had other solid organ transplantations~* 24 hours proteinuria\>2g~* SGPT/ALT，SGOT/AST or total bilirubin rising to more than double the normal level~* Patients suffering from serious infection lesions~* Patients have severe diarrhea or vomiting, peptic ulcer and/or defective absorption~* Patients have severe heart, lung disease, abnormal glucose tolerance or malignant tumor history~* Known contraindication to administration of Tacrolimus. Subject has known hypersensitivity to tacrolimus, or any of the product excipients~* Pregnancy or lactating women~* Patients have participated in another clinical trial in the past month~* Patient refuses to sign informed consent form~* Patient not willing to continue in the study and wants to withdraw from the study~* Poor adherence or lost to follow-up~* Violation of protocol~* Severe adverse events occurred need to withdraw the study according to investigator's judgment~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ADV group (Type: EXPERIMENTAL): Once daily
- PRG group (Type: EXPERIMENTAL): Twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* ENTO monotherapy (Group A): relapsed or refractory hematologic malignancies by World Health Organisation (WHO) criteria and who are not eligible to receive standard of care~* ENTO + cytarabine + daunorubicin (Group B): previously untreated AML by WHO criteria, who are deemed fit for cytarabine and daunorubicin (7+3) induction chemotherapy and are able to undergo up to 2 cycles of induction chemotherapy, as determined by the treating physician~* Must have been born in Japan and must not have lived outside of Japan for a period \> 1 year in the 5 years prior to Day 1 of study treatment~* Must be able to confirm the Japanese origin of their maternal and paternal ancestry~Key Exclusion Criteria:~* Known active central nervous system or leptomeningeal leukemic involvement~* Ongoing liver injury, or known infection with chronic active hepatitis C virus (HCV) or chronic active hepatitis B virus (HBV)~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ENTO monotherapy (Group A) (Type: EXPERIMENTAL): Participants with relapsed or refractory hematologic malignancies will receive ENTO twice daily of every 28-day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit.
- ENTO + cytarabine + daunorubicin (Group B) (Type: EXPERIMENTAL): Lead-in (Cycle 0): Participants with previously untreated AML will receive ENTO twice daily for 14 days.~Induction (Up to 2 cycles): ENTO in combination with daunorubicin and cytarabine for up to two 28-day cycles.~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants (who have achieved complete remission \[CR\] or morphologic complete remission with incomplete blood count recovery \[CRi\] and do not require or cannot proceed to allogeneic stem cell transplantation \[SCT\] and participants who are awaiting a donor or transitioning to allogeneic SCT per investigator discretion) will have the option to receive post-remission chemotherapy with ENTO twice daily in combination with high-dose cytarabine (Hi-DAC) for up to four 28-day cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Part A: Advanced solid tumors (including lymphoma without bone marrow involvement) for which standard treatment doesn't exist or is no longer effective.~* Part B: B-cell non-Hodgkin lymphoma that is not eligible for curative therapy or has relapsed.~* Relatively good overall health other than your cancer~Exclusion Criteria:~* Poor bone marrow function (not producing enough blood cells). Serious heart conditions. Poor liver or kidney function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues